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Abstract
Objective—To compare outcomes after six-month maintenance treatment of adults diagnosed 
with OCD based on DSM IV criteria who responded to acute treatment with serotonin reuptake 
inhibitors (SRIs) augmented by exposure therapy (EX/RP) or risperidone.
Method—A randomized trial was conducted at two academic sites from October 2006 through 
December 2012. In the Acute Phase, 100 patients on therapeutic SRI dose with at least moderate 
OCD severity were randomized to 8 weeks of EX/RP, risperidone, or pill placebo. Responders 
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entered the six-month Maintenance Phase, continuing the augmentation strategy they received 
acutely (30 EX/RP, 8 risperidone). Independent evaluations were conducted every month. The 
main outcome was the Yale-Brown Obsessive Compulsive Scale (Y-BOCS).
Results—Intent-to-treat analyses indicated that EX/RP yielded superior OCD outcomes after six-
month maintenance treatment than risperidone (Y-BOCS=10.95 versus 18.70;t(40)=2.76,P=.009); 
more patients randomized to EX/RP met response criteria (Y-BOCS decrease≥25%: 70% versus 
22.5%;P<.001) and achieved minimal symptoms (Y-BOCS≤12: 50% versus 5%;P<.001). During 
maintenance, OCD severity decreased slightly in both conditions (Y-BOCS decrease=2.2 points, 
P=.020). Lower Y-BOCS at entry to maintenance was associated with more improvement in both 
conditions (r(38)=.57, P <.001).
Conclusion—OCD patients on SRIs who responded to acute EX/RP or risperidone maintained 
their gains over six-month maintenance. Because EX/RP patients improved more during acute 
treatment than risperidone patients, and both maintained their gains during maintenance, EX/RP 
yielded superior outcomes six months later. The findings that 50% of patients randomized to 
EX/RP had minimal symptoms at six-month maintenance, a rate double that of prior studies, 
suggests that EX/RP maintenance helps maximize long-term outcome.
Trial Registration—Clinicaltrials.gov identifier: NCT00389493
Introduction
Serotonin reuptake inhibitors (SRIs, i.e., clomipramine and selective SRIs) are the only 
medications approved by the Food and Drug Administration to treat obsessive-compulsive 
disorder OCD1. Although many patients respond, few achieve minimal symptoms from an 
SRI alone2. For partial SRI responders, practice guidelines1 recommend adding either 
cognitive-behavioral therapy (CBT) consisting of Exposure and Response Prevention 
(EX/RP) or antipsychotics. This paper compared the outcome of these two SRI 
augmentation strategies when continued for six months after acute treatment.
Randomized controlled trials and naturalistic studies find that adding EX/RP to SRIs 
improves outcomes in adults with OCD, irrespective of whether they responded to the 
SRI3–7. In one prior study of adults with OCD on SRIs who received 8 weeks of EX/RP 
augmentation8, 40 of 54 (74%) responded to acute treatment, and 22 of 54 (41%) met 
response criteria after six months of maintenance.
Meta-analyses9, 10 estimate that up to one-third of OCD patients on SRIs respond acutely to 
antipsychotic augmentation. However, the long-term response to antipsychotic augmentation 
has not been systematically studied. Matsunaga and colleagues11 assigned OCD patients on 
SRIs (based on their degree of response) to continued SRI plus EX/RP (n=46, for SRI 
responders) or continued SRI plus EX/RP plus an antipsychotic (n=44, for SRI non-
responders). At the time of assignment and one year later, the SRI nonresponders (receiving 
continued SRI, EX/RP, and antipsychotic) had significantly more OCD symptoms than the 
SRI responders (receiving continued SRI and EX/RP). Also, mean improvement in OCD 
symptoms over the year was smaller for the SRI nonresponders. These findings led the 
authors to question the long-term effectiveness of antipsychotic augmentation. However, 
because treatment assignment was not random but based on SRI response and both groups 
Foa et al. Page 2
J Clin Psychiatry. Author manuscript; available in PMC 2015 August 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
received EX/RP, the study could not ascertain the long-term effects of augmenting SRIs 
with antipsychotics alone.
To compare the long term effects of EX/RP versus risperidone augmentation, we analyzed 
data from a trial that randomized 100 OCD adults on SRIs to EX/RP, risperidone, or pill 
placebo. After 8 weeks of acute treatment, EX/RP was superior to both risperidone and pill 
placebo12. Responders then continued to receive their assigned treatment for an additional 
six months. We hypothesized that after the six-month Maintenance Phase, patients 
randomized to EX/RP would have superior OCD outcome to those randomized to 
risperidone.
Method
Setting
Data came from a randomized controlled trial conducted at two academic outpatient clinics 
in Philadelphia and New York City. Study details appear elsewhere12. Enrollment began in 
2007; data collection ended in 2012. Each site’s institutional review board approved the 
study. Participants provided written informed consent prior to entry.
Participants
Eligible participants were adults (18–70 years) with a principal diagnosis of OCD (≥ one 
year), who were receiving an SRI at a stable dose for at least 12 weeks and yet remained 
symptomatic (Yale Brown Obsessive-Compulsive Scale Y-BOCS13, 14 ≥ 16). Exclusion 
criteria included bipolar and psychotic disorders, substance abuse or dependence in the past 
3 months, prominent suicidal ideation, a 17-item Hamilton Depression Rating Scale 
HDRS15 score indicating severe depression (> 25), or hoarding as the only OCD symptom. 
Other Axis I diagnoses were permitted if OCD was the most severe and impairing. Patients 
were excluded if they had previously received risperidone (≥ 0.5 mg/day for 8 weeks) or 
EX/RP (≥ 8 sessions over 2 months) while taking an SRI (as described above) or were 
receiving their first SRI with no response, as practice guidelines1 recommend switching to 
another SRI in such cases. Trained clinicians determined eligibility. Trained raters with 
expertise in OCD and related disorder confirmed psychiatric diagnoses prior to study entry 
using the Structured Clinical Interview for DSM-IV16. Treatment history was confirmed 
with the referring clinician and/or chart review.
Study Procedures
During the Acute Phase, 100 adults with OCD on a stable SRI dose were randomized to 
augmentation by EX/RP (n=40), risperidone (n=40), or pill placebo (n=20) (Figure 1). 
Patients randomized to EX/RP saw a study therapist for two planning/introductory sessions 
and 15 twice-weekly 90-minute EX/RP sessions17, and met with a study psychiatrist for SRI 
maintenance at Weeks 0, 4, and 8. Those randomized to risperidone or pill placebo met with 
a study psychiatrist at Weeks 0, 1, 2, 3, 4, 6, and 8.
Responders at Week 8 (Y-BOCS decrease ≥ 25%) were eligible to enter the six-month 
Maintenance Phase; non-responders were referred for open treatment. During maintenance, 
Foa et al. Page 3
J Clin Psychiatry. Author manuscript; available in PMC 2015 August 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
responders continued their SRI at the same dose (meeting monthly with their study 
psychiatrist) and the augmentation strategy to which they were originally assigned (EX/RP 
with their study therapist or risperidone). For EX/RP patients, maintenance sessions 
included exposures, ritual prevention (following standard procedures17) and instruction in 
relapse prevention. The length and frequency of maintenance EX/RP sessions depended 
upon the patient’s OCD severity. Patients who achieved minimal symptoms at the end of the 
Acute Phase (Y-BOCS ≤ 12) received four weekly 45-minute sessions followed by 45-
minute sessions every other week for the duration of the Maintenance Phase. The remaining 
patients received 90-minute EX/RP sessions twice-weekly until they achieved minimal 
symptoms (Y-BOCS ≤ 12) or had received 15 additional 90-minute EX/RP sessions. 
Subsequently, patients received four weekly 45-minute sessions followed by 45-minute 
sessions every other week until the end of the Maintenance Phase. Risperidone patients 
received ongoing risperidone, with the intent of maintaining the same dose used during the 
Acute Phase. Consistent with clinical practice, however, medication decreases for side 
effects and increases for OCD symptom exacerbations were allowed, so long as the dose 
stayed between 0.5 and 4.0 mg/day, reflecting doses used in prior risperidone augmentation 
studies in OCD18–20.
Assessments
Sociodemographic features and treatment history were assessed at baseline. Independent 
evaluators (IEs), blind to treatment, evaluated patients every four weeks during the Acute 
(weeks 0,4,8) and Maintenance Phases (weeks 12,16,20,24,28,32). The IE training included 
reviewing tapes of senior IEs conducting evaluations, re-rating these tapes with a goal of 
achieving at least 90% agreement with the original ratings, and observing at least 2 live 
evaluations by senior IEs. In addition, IEs conducted at least 2 evaluations with the senior IE 
in the room, with the goal of achieving at least 90% agreement with the senior IE. During 
the study, IEs audiotaped their assessments and these were sent to the IE supervisor (Dr. 
Jonathan Huppert) for review. IEs at each site conducted ongoing reliability meetings for the 
Y-BOCS in which all the IEs rated the audiotaped assessments. Ratings were compared 
afterward and any divergences were resolved. In addition, IEs from both sites met with Dr. 
Huppert in person or by conference call twice per year, and taped interviews from each site 
were formally rated by all IEs to assess inter-rater and cross-site reliability, and any points 
of divergence were resolved. Intraclass correlations (ICC) between IEs were extremely high 
(e.g., Y-BOCS ICC=0.99; 95% CI=0.97, 1.00).
IEs administered the Y-BOCS13, 14 to assess OCD severity, the 17-item HRDS15 to assess 
depressive severity, and the Brown Assessment of Beliefs (BABS21) to assess degree of 
insight about the main OCD belief. Every four weeks, patients also completed the Quality of 
Life Satisfaction Scale-Short Form (QLESQ22), the Social Adjustment Scale-Self Report 
(SAS23), and the Obsessive-Compulsive Inventory-Revised (OCI-R24).
Study psychiatrists assessed side effects at each visit using a modified version of the 
Systemic Assessment for Treatment Emergent Events that included 26 items (each rated 
absent, mild, moderate, or severe)25. Vital signs and weight were measured at each visit; 
height was measured at baseline and used to calculate Body Mass Index (BMI=mass [kg]/
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[height (m)]2). Psychiatrists assessed tics using the Yale Global Tic Severity Scale26 at 
baseline, and extrapyramidal symptoms using the Simpson-Angus Scale27 and Barnes 
Akathisia Scale28 at each visit, and the Abnormal Involuntary Movement Scale29, 30 at 
Weeks 0 and 8.
Details about the training of study staff and the reliability of assessments are provided 
elsewhere12.
Data Analysis
While focusing on the Maintenance Phase, we included all randomized participants in our 
primary analyses, since those who entered maintenance did not comprise a randomized 
sample and therefore would render the results uninterpretable. Of the 20 placebo 
participants, only three were acute phase responders12, and two entered maintenance. Thus, 
the analyses focus on the 80 participants originally randomized to EX/RP or risperidone 
augmentation.
The primary outcome was the Y-BOCS, which was analyzed using linear mixed models 
(LMMs). LMMs allow the inclusion of all subjects, irrespective of missing data. 
Importantly, LMMs are particularly suitable for analyzing maintenance trials such as ours 
because they produce accurate and unbiased results when data are missing due to patients 
being dropped because of non-response to treatment31. Indeed, studies show that LMMs 
accurately estimate the results for the entire initial randomized sample even when almost 
90% of subjects are dropped from the study due to non-response to treatment31, and even 
when sample sizes are very small32.
Two separate LMMs were employed. To estimate the means at each assessment point, our 
first LMM used indicator variables to code each assessment point. This model freely 
estimates each mean at each assessment without constraining them to fit any particular 
growth curve model. To estimate the slopes of Y-BOCS change, our second LMM used a 
linear piecewise growth curve model33, allowing the slopes to change from the Acute to the 
Maintenance Phase (see Figure 2). As preliminary analyses showed treatment site was 
unrelated to outcome (Ps >.184), it was dropped from further analyses.
As secondary analyses, a Fisher’s Exact Test examined the proportion in each treatment 
group who met response criteria at the end of maintenance (Y-BOCS decrease ≥ 25%) or 
excellent response criteria (Y-BOCS ≤ 12), thereby using the criteria employed in prior 
studies to enable direct comparison2, 5 for these analyses, the last available observation was 
used. The LMMs were used to examine outcomes from our secondary measures (SAS-SR, 
QLESQ, HAM-D, BABS, and OCI-R). The significance level for all tests was α=.05.
Results
Sample
As shown in Figure 1, of the 100 patients randomized, 44 patients were judged responders 
(Y-BOCS decrease ≥ 25%) at the end of the Acute Phase. Forty entered the Maintenance 
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Phase (30 EX/RP, 8 risperidone, 2 placebo), and 31 completed it (26 EX/RP, 3 risperidone, 
2 placebo). The reasons for dropout are detailed in Figure 1.
Demographic and clinical characteristics of the 30 EX/RP and 8 risperidone patients who 
entered maintenance are presented in Table 1; the proportion who completed maintenance 
was significantly higher in EX/RP than in risperidone (P=.01). Of the risperidone patients, 
four continued on the same dose they were receiving at the end of the Acute Phase; four 
decreased their dose during maintenance to reduce side effects. The final mean risperidone 
dose of these 8 patients was 1.47 (SD=0.91, range=0.5 to 3.0 mg/day). Twenty of the 30 
EX/RP patients who entered maintenance received additional 90-minute sessions 
(mean=10.30, SD=4.64, range 1–15); seven received the maximum 15 sessions.
Primary Outcome: Y-BOCS
a. Y-BOCS over time—At the end of maintenance treatment, patients originally 
randomized to acute EX/RP augmentation had significantly lower mean Y-BOCS scores 
than those originally randomized to risperidone (see Table 2; b=7.75, t(40)=2.76, P=.009, 
d=.87). However, during maintenance, the groups did not significantly differ from one 
another with respect to change in Y-BOCS (see Figure 2; b=.12, t(33)=1.11, P=.276 for the 
Treatment × Time interaction during maintenance). During maintenance, both groups 
showed a small, statistically significant Y-BOCS improvement (b=−.09, t(26)=−2.47, P=.
020, d=.24) of 2.2 points.
Exploratory analyses indicated that Y-BOCS change during maintenance was significantly 
related to Y-BOCS at entry to maintenance, with lower Y-BOCS associated with faster Y-
BOCS decreases in both conditions (r(38)=.57, P <.001). A post-hoc cluster analysis of Y-
BOCS slopes during maintenance, Y-BOCS severity at entry to maintenance, and amount of 
therapy received during maintenance suggested a complex relationship between amount of 
maintenance EX/RP treatment in minutes (summing 45 and 90-minute sessions) and 
maintenance outcome: those who improved the most during maintenance (average Y-BOCS 
slope of −0.20) had minimal OCD symptoms at entry to maintenance (Y-BOCS=8.60 
[SD=5.97]) and received on average 680 minutes [SD=155] of maintenance treatment; those 
who improved less (average Y-BOCS slope of −0.05) had minimal OCD symptoms at entry 
(Y-BOCS=8.67 [SD=3.56]) but received less maintenance treatment than the former patients 
(255 minutes [SD=203]; and those whose OCD symptoms did not change during 
maintenance (average Y-BOCS slope of 0) had the most OCD symptoms at entry to 
maintenance (Y-BOCS=15.14 [SD=3.18]) and received the most maintenance treatment 
(1578 minutes [SD=202]).
b. Response Rates—By the end of maintenance treatment, significantly more patients 
originally randomized to EX/RP than to risperidone achieved response status (Y-BOCS 
decrease≥25%: 28 of 40 [70.0%] in EX/RP; 8 of 40 [20.0%] in risperidone; Fisher’s Exact 
Test P<.001), and significantly more patients randomized to EX/RP achieved minimal 
symptoms (Y-BOCS≤12: 20 of 40 [50.0%] in EX/RP; 2 of 40 [5.0%] in risperidone; 
Fisher’s Exact Test P<.001). However, of the 30 EX/RP and 8 risperidone responders who 
entered maintenance, the proportion who maintained their response status did not 
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significantly differ by treatment (28 of 30 [93.3%] in EX/RP; 8 of 8 [100%] in risperidone; 
Fisher’s Exact Test P=.619).
Secondary Outcomes: Change in Secondary Measures Over Time
At the end of maintenance treatment, patients originally randomized to EX/RP had 
significantly more improvement than patients randomized to risperidone on all secondary 
outcomes, including measures of depression, functioning, and quality of life(Ps<.047, ds=.
64 −1.16), except the BABS, a measure of insight (P = .128; see Table 2). Notably, during 
maintenance, there were no group differences in the rates of change over time on any of the 
secondary outcomes (all Ps>.207 for the Treatment × Time interactions). The slopes of 
improvement during maintenance for both treatment conditions were significant (small to 
medium in size) for all secondary outcomes (Ps<.01, ds=.19–.52), with the exception of the 
QLESQ (P=.183).
Discussion
This paper describes six-month outcomes after augmenting SRIs with EX/RP or risperidone 
in adults with OCD. EX/RP augmentation was superior to risperidone augmentation in 
reducing OCD and depression severity and improving quality of life and functioning not 
only after acute treatment12 but also six months later. By the end of maintenance, 50% of 
patients initially randomized to EX/RP augmentation achieved minimal OCD symptoms 
compared to 5% of those randomized to risperidone augmentation. These data support using 
EX/RP over antipsychotics for augmenting SRIs in OCD.
To our knowledge, this is the only study to systematically investigate the long term outcome 
of augmenting SRIs with antipsychotics in OCD. Contrary to our expectations, few patients 
responded acutely to risperidone (9 of 40), and eight agreed to enter maintenance. Although 
these eight maintained their OCD gains as long as they were assessed, five did not complete 
maintenance due to intolerable side effects or increased depression. Thus, risperidone, albeit 
acutely efficacious for some, was not very effective over time in our sample. The three who 
completed maintenance were receiving risperidone doses (0.5, 0.75, and 1.0 mg/day) below 
the mean maximum dose during the Acute (2.2 mg/day) or Maintenance Phases (1.5 mg/
day). Low risperidone doses may increase long-term tolerability.
It is important to note that those who responded to augmenting SRIs with EX/RP were likely 
to maintain their gains (or slightly improve) for an additional six months with maintenance 
treatment. Thus, even though EX/RP treatment yielded very substantial acute improvement, 
there was no evidence of a tendency to regress or rebound during maintenance. This result is 
consistent with our data from a prior randomized trial5 in which patients responding to 
augmenting SRIs with EX/RP were followed for an additional six months8. However, 
despite similar rates of acute response to EX/RP augmentation (80% in the current trial12 
and 74% in the earlier trial5), more patients in the current trial met response criteria after six 
months maintenance (70% versus 41%) and achieved minimal symptoms (50% versus 
24%). Differences in study designs may explain the disparity: patients in the current study 
received more frequent 45-minute maintenance sessions (twice monthly versus once 
monthly) and could also receive up to 15 additional 90-minute EX/RP sessions during 
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maintenance if they did not achieve minimal OCD symptoms after the Acute Phase. This 
suggests that additional treatment may have helped some patients maintain their acute gains. 
Although the maintenance treatment in the current study is much more intensive (and hence 
more costly) than the maintenance treatment in the previous study, the superior six month 
outcomes observed in the current study may warrant the additional investment.
On average, patients randomized to EX/RP and risperidone augmentation exhibited 
continued improvement during maintenance on most outcomes, but these gains were 
clinically small. Thus outcome at the end of the Maintenance Phase primarily reflected 
successful maintenance of acute response, regardless of the treatment received. Indeed, 
lower OCD severity at entry to maintenance was associated with better outcome in both 
conditions.
The lack of treatment group differences in the rate of improvement during maintenance in 
the present study was initially surprising given that 20 of 30 EX/RP patients received 
additional 90-minute treatment sessions during maintenance. However, those who received 
additional 90-minute sessions were not a random sample: patients received these 90-minute 
sessions until they either achieved minimal symptoms or had 15 sessions. In fact, a post-hoc 
analysis suggested a complex relationship between maintenance outcome and amount of 
maintenance EX/RP treatment (summing 45 and 90-minute sessions): those whose OCD 
improved the most during maintenance had minimal OCD symptoms at entry to 
maintenance and received some maintenance treatment; those who improved less had 
minimal OCD symptoms at entry but received less maintenance treatment than the former; 
and those whose OCD symptoms did not change during maintenance did not achieve 
minimal symptoms by the end of the Acute Phase, continued to receive 90-minute EX/RP 
sessions, and thus received the most maintenance treatment. These findings suggest that 
achieving minimal OCD severity with acute treatment and receiving some maintenance 
therapy were both important ingredients for maximizing EX/RP long-term outcome. 
However, our study was not designed to investigate this issue prospectively. Future studies 
should also develop cost-effective methods for delivering EX/RP and should examine what 
factors determine who will benefit most from maintenance therapy.
This study has several limitations. The first is sample size. For ethical considerations, non-
responders to acute treatment were referred for other treatments. Thus, only 8 risperidone 
patients entered the Maintenance Phase, which calls for caution in generalizing the long 
term outcome of risperidone from these data. Nevertheless, studies show that LMM growth 
models in which almost 90% of cases are dropped for non-response still produce unbiased 
and accurate estimates of the actual population parameters for the entire initial randomized 
sample31. A second limitation is that the Maintenance Phase lasted only six months. 
However, it is difficult to control all treatment that patients receive over an extended period 
of time, which is why studies with longer follow-up periods34, 35 adopt naturalistic designs. 
Finally, patients receiving EX/RP were not blind to their treatment and had more clinician 
contact than those receiving risperidone. Yet, our prior study5 that compared EX/RP 
augmentation to a psychotherapy control suggests that blindness to therapy and clinician 
contact alone cannot explain the superiority of EX/RP.
Foa et al. Page 8
J Clin Psychiatry. Author manuscript; available in PMC 2015 August 04.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
In summary, OCD patients on SRIs who responded acutely to EX/RP or risperidone 
augmentation were likely to maintain their gains over six months with some continued 
treatment. However, many more EX/RP than risperidone patients responded acutely and 
thus entered the Maintenance Phase. As a result, augmenting SRIs with EX/RP yielded 
superior outcomes than risperidone six months later. It is important to note that during the 8-
week Acute Phase of treatment, of the 50 patients who received EX/RP augmentation, 30 
were responders, whereas of the 50 who received risperidone, only 8 were responders. 
Taken together, the results of the Acute and the Maintenance treatment phases strongly 
support augmenting SRIs with EX/RP rather than with risperidone in adults with OCD. The 
data also suggest that ongoing EX/RP treatment can help many patients maintain their acute 
gains. Developing effective and cost-effective ways to deliver EX/RP to OCD patients will 
advance public health.
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Clinical Points
1. While serotonin reuptake inhibitors are the only medications approved by the 
FDA to treat OCD, many patients remain quite symptomatic.
2. For partial SRI responders, practice guidelines recommend adding either 
Exposure and Response Prevention (EX/RP) or antipsychotics (e.g., 
risperidone).
3. The results strongly support augmenting SRIs with EX/RP rather than with 
risperidone in adults with OCD.
4. The results also suggest that extending EX/RP beyond the 17 acute treatment 
sessions (up to 30 sessions) helps many patients maintain their gains.
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Figure 1. Flow Chart of Patients in Study
* Reasons for not completing maintenance:
EX/RP: increasing depression (n=1); wanted to change SRI medication (n=1), unable to 
travel to site (n=1), lost to follow-up (n=1);
Risperidone: side effects too great (n=2); increasing depression (n=2); lost to follow-up 
(n=1)
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Figure 2. Change in Severity of Obsessive-Compulsive Disorder
Plot of the piecewise growth curve for the Yale-Brown Obsessive Compulsive Scale (Y-
BOCS) for patients receiving EX/RP (n=40) or risperdone (n=40). At the end of the 
Maintenance Phase, those randomized to EX/RP had significantly lower mean Y-BOCS 
scores (Week 32: b=7.75, P=.009). Slopes during the Maintenance Phase did not differ 
(Weeks 8–32: b=.12, P=.276).
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Table 1
Characteristics of Entrants to the Maintenance Phase
EX/RP
(n=30)
RIS
(n=8)
Age, mean (SD), y 34.47 (13.09) 42.25 (11.73)
Female, No. (%) 17 (57) 4 (50)
White, No. (%) 28 (93) 8 (100)
Marital Status, No. (%):
  Single 17 (57) 3 (38)
  Married-Partnered 11 (37) 3 (38)
  Divorced-Separated 2 (7) 2 (25)
Week 0 Y-BOCS, mean (SD) 27.50 (3.88) 24.13 (4.29)
Week 8 Y-BOCS, mean (SD) 11.67 (5.36) 11.13 (6.71)
Week 0 HDRS, mean (SD) 6.87 (5.18) 10.00 (6.09)
Week 8 HDRS, mean (SD) 4.30 (3.71) 5.13 (3.23)
Abbreviations: EX/RP, Exposure and Ritual Prevention; HDRS, Hamilton Depression Rating Scale; SD, standard deviation; SMT, Stress 
Management Training; y, year; Y-BOCS, Yale-Brown Obsessive Compulsive Scale.
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